Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708

Rajkumar SV (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91(1):90–100. https://doi.org/10.1002/ajh.24236

Article  CAS  PubMed Central  Google Scholar 

Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111(5):2516–2520. https://doi.org/10.1182/blood-2007-10-116129

Article  CAS  PubMed Central  Google Scholar 

Bobin A, Leleu X (2022) Recent advances in the treatment of multiple myeloma: a brief review. Fac Rev 11:28. https://doi.org/10.12703/r/11-28

Article  CAS  PubMed Central  Google Scholar 

Dima D, Ullah F, Mazzoni S, Williams L, Faiman B, Kurkowski A et al (2023) Management of relapsed-refractory multiple myeloma in the era of Advanced therapies: evidence-based recommendations for routine clinical practice. Cancers (Basel) 15(7). https://doi.org/10.3390/cancers15072160

Lasica M, Anderson MA (2021) Review of Venetoclax in CLL, AML and multiple myeloma. J Pers Med 11(6). https://doi.org/10.3390/jpm11060463

Ball BJ, Famulare CA, Stein EM, Tallman MS, Derkach A, Roshal M et al (2020) Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv 4(13):2866–2870. https://doi.org/10.1182/bloodadvances.2020001482

Article  PubMed Central  Google Scholar 

Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ et al (2021) Long-term follow-up of patients with relapsed or refractory Non-hodgkin Lymphoma Treated with Venetoclax in a phase I, first-in-human study. Clin Cancer Res 27(17):4690–4695. https://doi.org/10.1158/1078-0432.CCR-20-4842

Article  CAS  PubMed Central  Google Scholar 

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B et al (2017) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood 130(22):2401–2409. https://doi.org/10.1182/blood-2017-06-788786

Article  CAS  Google Scholar 

Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ et al (2021) Phase I study of Venetoclax Plus Daratumumab and Dexamethasone, with or without Bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol 39(32):3602–3612. https://doi.org/10.1200/JCO.21.00443

Article  CAS  PubMed Central  Google Scholar 

Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A et al (2021) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv 5(19):3748–3759. https://doi.org/10.1182/bloodadvances.2020004146

Article  CAS  PubMed Central  Google Scholar 

Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E et al (2023) Venetoclax in biomarker-selected multiple myeloma patients: impact of exposure on clinical efficacy and safety. Hematol Oncol 20230923 ed

Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F et al (2016) Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biol Ther 17(7):769–777. https://doi.org/10.1080/15384047.2016.1192086

Article  CAS  PubMed Central  Google Scholar 

Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al (2005) Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65(14):6282–6293. https://doi.org/10.1158/0008-5472.CAN-05-0676

Article  CAS  Google Scholar 

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38. https://doi.org/10.1016/S1470-2045(15)00464-7

Article  CAS  Google Scholar 

Matulis SM, Gupta VA, Nooka AK, Hollen HV, Kaufman JL, Lonial S et al (2016) Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax. Leukemia 30(5):1086–1093. https://doi.org/10.1038/leu.2015.350

Article  CAS  Google Scholar 

Kaufman JL, Gasparetto C, Kovacsovics et al First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma. Presented at: 2023 International Myeloma Society Annual Meeting; September 27–30, 2023; Athens, Greece. Abstract OA-29

Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J et al (2017) Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos 45(3):294–305. https://doi.org/10.1124/dmd.116.071613

Article  CAS  Google Scholar 

Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH (2016) Clinical predictors of Venetoclax Pharmacokinetics in Chronic lymphocytic leukemia and Non-hodgkin’s Lymphoma patients: a Pooled Population Pharmacokinetic Analysis. AAPS J 18(5):1192–1202. https://doi.org/10.1208/s12248-016-9927-9

Article  CAS  Google Scholar 

Salem AH, Dunbar M, Agarwal SK (2017) Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs 28(8):911–914. https://doi.org/10.1097/CAD.0000000000000522

Article  CAS  Google Scholar 

Chiney MS, Menon RM, Bueno OF, Tong B, Salem AH (2018) Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin. Xenobiotica 48(9):904–910. https://doi.org/10.1080/00498254.2017.1381779

Article  CAS  Google Scholar 

Freise KJ, Hu B, Salem AH (2018) Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics. Eur J Clin Pharmacol 74(4):413–421. https://doi.org/10.1007/s00228-017-2403-3

Article  CAS  Google Scholar 

Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH (2018) Effect of azithromycin on Venetoclax Pharmacokinetics in healthy volunteers: implications for Dosing Venetoclax with P-gp inhibitors. Adv Therapy 35(11):2015–2023. https://doi.org/10.1007/s12325-018-0793-y

Article  CAS  Google Scholar 

Noorani B, Menon RM, Chen X, Marsh KC, Huang W, Gupta S et al (2023 Oct) Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis. Br J Clin Pharmacol 19. https://doi.org/10.1111/bcp.15935

Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD et al (2022) Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naive acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40(2):269–279. https://doi.org/10.1002/hon.2964

Article  CAS  PubMed Central  Google Scholar 

Samineni D, Huang W, Gibiansky L, Ding H, Zhang R, Li C et al (2022) Population Pharmacokinetics and exposure-response analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and previously untreated patients with diffuse large B cell lymphoma. Adv Therapy 39(1):598–618. https://doi.org/10.1007/s12325-021-01919-z

Article  CAS  Google Scholar 

Badawi M, Coppola S, Eckert D, Gopalakrishnan S, Engelhardt B, Doelger E et al (2023) Venetoclax in biomarker-selected multiple myeloma patients: impact of exposure on clinical efficacy and safety. Hematological oncology. 23. https://doi.org/10.1002/hon.3222

Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH (2023) Pooled Population pharmacokinetic analyses of Venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials. J Clin Pharmacol 63(8):950–960. https://doi.org/10.1002/jcph.2248

Article  CAS  Google Scholar 

Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA et al (2017) Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Pharmacokinet 56(5):515–523. https://doi.org/10.1007/s40262-016-0453-9

Article  Google Scholar 

Parikh A, Gopalakrishnan S, Freise KJ, Verdugo ME, Menon RM, Mensing S et al (2018) Exposure-response evaluations of venetoclax efficacy and safety in patients with non-hodgkin lymphoma. Leuk Lymphoma 59(4):871–879. https://doi.org/10.1080/10428194.2017.1361024

Article  CAS  Google Scholar 

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM et al (2017) Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol 35(4):679–684. https://doi.org/10.1002/hon.2373

Article  CAS  Google Scholar 

Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W et al (2019) Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure-response analysis. Hematol Oncol 37(4):464–473. https://doi.org/10.1002/hon.2646

Article  CAS  Google Scholar 

Freise KJ, Jones AK, Verdugo ME, Menon RM, Maciag PC, Salem AH (2017) Moving Beyond Maximum tolerated dose for targeted oncology drugs: Use of Clinical Utility Index to optimize Venetoclax Dosage in multiple myeloma patients. Clin Pharmacol Ther. https://doi.org/10.1002/cpt.712

Article  Google Scholar 

Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C et al (2020) Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 21(12):1630–1642. https://doi.org/10.1016/s1470-2045(20)30525-8

Article  CAS  Google Scholar 

Daniele P, Mamolo C, Cappelleri JC, Bell T, Neuhof A, Tremblay G et al (2022) Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. PLoS ONE 17(5):e0267979. https://doi.org/10.1371/journal.pone.0267979

Article  CAS